These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 11744479)
1. Nilutamide: possible utility as a second-line hormonal agent. Desai A; Stadler WM; Vogelzang NJ Urology; 2001 Dec; 58(6):1016-20. PubMed ID: 11744479 [TBL] [Abstract][Full Text] [Related]
2. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. Kassouf W; Tanguay S; Aprikian AG J Urol; 2003 May; 169(5):1742-4. PubMed ID: 12686822 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. Nakabayashi M; Regan MM; Lifsey D; Kantoff PW; Taplin ME; Sartor O; Oh WK BJU Int; 2005 Oct; 96(6):783-6. PubMed ID: 16153200 [TBL] [Abstract][Full Text] [Related]
4. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy. Davis NB; Ryan CW; Stadler WM; Vogelzang NJ BJU Int; 2005 Oct; 96(6):787-90. PubMed ID: 16153201 [TBL] [Abstract][Full Text] [Related]
5. Nilutamide: an antiandrogen for the treatment of prostate cancer. Dole EJ; Holdsworth MT Ann Pharmacother; 1997 Jan; 31(1):65-75. PubMed ID: 8997470 [TBL] [Abstract][Full Text] [Related]
6. Antiandrogen withdrawal syndrome with nilutamide. Huan SD; Gerridzen RG; Yau JC; Stewart DJ Urology; 1997 Apr; 49(4):632-4. PubMed ID: 9111642 [TBL] [Abstract][Full Text] [Related]
11. Which is the optimal antiandrogen for use in combined androgen blockade of advanced prostate cancer? The transition from a first- to second-generation antiandrogen. Sarosdy MF Anticancer Drugs; 1999 Oct; 10(9):791-6. PubMed ID: 10587288 [TBL] [Abstract][Full Text] [Related]
12. Antiandrogen monotherapy in the management of advanced prostate cancer. Kaisary AV Eur Urol; 1997; 31 Suppl 2():14-9; discussion 24-7. PubMed ID: 9074906 [TBL] [Abstract][Full Text] [Related]
13. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer. Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272 [TBL] [Abstract][Full Text] [Related]
15. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T; J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218 [TBL] [Abstract][Full Text] [Related]
16. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. Schellhammer PF; Venner P; Haas GP; Small EJ; Nieh PT; Seabaugh DR; Patterson AL; Klein E; Wajsman Z; Furr B; Chen Y; Kolvenbag GJ J Urol; 1997 May; 157(5):1731-5. PubMed ID: 9112515 [TBL] [Abstract][Full Text] [Related]
17. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study. Raina R; Pahalajani G; Agarwal A; Zippe C Asian J Androl; 2007 Mar; 9(2):253-8. PubMed ID: 17334592 [TBL] [Abstract][Full Text] [Related]
18. Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project. Decensi AU; Boccardo F; Guarneri D; Positano N; Paoletti MC; Costantini M; Martorana G; Giuliani L J Urol; 1991 Aug; 146(2):377-81. PubMed ID: 1856935 [TBL] [Abstract][Full Text] [Related]
19. [Alternative antiandrogen therapy with flutamide in patients with castration-resistant prostate cancer : a single center experience]. Takada T; Ishizuya Y; Okada T; Ueda T; Inoue H; Hara T Hinyokika Kiyo; 2011 Jun; 57(6):291-5. PubMed ID: 21795830 [TBL] [Abstract][Full Text] [Related]
20. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy. Migliari R; Muscas G; Murru M; Verdacchi T; De Benedetto G; De Angelis M Arch Ital Urol Androl; 1999 Dec; 71(5):293-302. PubMed ID: 10673793 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]